Nifty
:
24426.85
Sensex
:
79809.65
-74.05 (-0.30%)
-270.92 (-0.34%)
Nifty
Sensex
:
:
24426.85
79809.65
-74.05 (-0.30%)
-270.92 (-0.34%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1894.90
29-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1902.4
  •  1917.7
  •  1890
  •  1902.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  865960
  •  1646440086.1
  •  2402.9
  •  1795.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 86,468.20
  • 23.37
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 88,402.52
  • 0.63%
  • 4.71

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.90%
  • 0.28%
  • 5.23%
  • FII
  • DII
  • Others
  • 21.25%
  • 23.99%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.85
  • 8.41
  • 10.92

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 15.51
  • 25.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.82
  • 21.98
  • 96.87

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.81
  • 35.91
  • 40.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.58
  • 4.05
  • 4.58

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.42
  • 18.26
  • 13.21

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
42.05
71.95
88.23
88.53
P/E Ratio
45.06
26.34
21.48
21.40
Revenue
19656
22192
25415
26685
EBITDA
3800
5278
6346
6331
Net Income
1914
3282
4021
4046
ROA
8.2
12.3
14.9
13.2
P/B Ratio
4.19
5.03
4.19
3.58
ROE
14.31
20.84
21.22
18.07
FCFF
2483
1192
3329
3712
FCFF Yield
2.76
1.32
3.7
4.12
Net Debt
1092
1246
-2061
-5232
BVPS
452.14
376.77
452.3
528.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
6,268.34
5,600.33
11.93%
5,667.13
4,960.79
14.24%
5,767.71
5,197.41
10.97%
5,672.73
5,038.56
12.59%
Expenses
4,541.10
4,359.36
4.17%
4,345.96
3,963.94
9.64%
4,411.81
4,159.47
6.07%
4,332.37
4,120.80
5.13%
EBITDA
1,727.24
1,240.97
39.18%
1,321.17
996.85
32.53%
1,355.90
1,037.94
30.63%
1,340.36
917.76
46.05%
EBIDTM
27.55%
22.16%
23.31%
20.09%
23.51%
19.97%
23.63%
18.21%
Other Income
79.04
67.78
16.61%
56.95
29.25
94.70%
53.71
29.37
82.87%
42.29
40.40
4.68%
Interest
91.76
68.01
34.92%
89.10
71.29
24.98%
66.89
74.01
-9.62%
70.87
80.64
-12.12%
Depreciation
298.98
247.71
20.70%
393.18
457.10
-13.98%
271.45
257.20
5.54%
256.92
247.85
3.66%
PBT
1,415.54
993.03
42.55%
895.84
497.71
79.99%
1,071.27
736.10
45.53%
1,054.86
629.67
67.53%
Tax
194.08
187.49
3.51%
113.46
129.49
-12.38%
212.41
117.40
80.93%
195.38
134.35
45.43%
PAT
1,221.46
805.54
51.63%
782.38
368.22
112.48%
858.86
618.70
38.82%
859.48
495.32
73.52%
PATM
19.49%
14.38%
13.81%
7.42%
14.89%
11.90%
15.15%
9.83%
EPS
26.69
17.57
51.91%
16.92
7.89
114.45%
18.74
13.46
39.23%
18.69
10.76
73.70%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
23,375.91
22,707.90
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
Net Sales Growth
12.40%
13.48%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
 
Cost Of Goods Sold
6,869.62
5,818.18
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
Gross Profit
16,506.29
16,889.72
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
GP Margin
70.61%
74.38%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
Total Expenditure
17,631.24
17,430.38
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
Power & Fuel Cost
-
479.09
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
% Of Sales
-
2.11%
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
Employee Cost
-
3,964.20
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
% Of Sales
-
17.46%
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
Manufacturing Exp.
-
3,006.40
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
% Of Sales
-
13.24%
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
General & Admin Exp.
-
2,514.00
2,221.05
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
% Of Sales
-
11.07%
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
Selling & Distn. Exp.
-
1,417.19
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
% Of Sales
-
6.24%
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
Miscellaneous Exp.
-
231.32
286.67
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
870.29
% Of Sales
-
1.02%
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
EBITDA
5,744.67
5,277.52
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
EBITDA Margin
24.58%
23.24%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
Other Income
231.99
201.61
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
Interest
318.62
294.87
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
Depreciation
1,220.53
1,169.26
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
PBT
4,437.51
4,015.00
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
Tax
715.33
708.74
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
Tax Rate
16.12%
17.65%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
PAT
3,722.18
3,281.62
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
PAT before Minority Interest
3,699.34
3,306.26
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
Minority Interest
-22.84
-24.64
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
PAT Margin
15.92%
14.45%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
PAT Growth
62.70%
71.41%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
 
EPS
81.50
71.86
41.92
9.42
-33.46
26.61
-5.99
13.39
5.42
55.82
49.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
17,203.50
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
Share Capital
91.32
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
Total Reserves
17,028.20
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
Non-Current Liabilities
2,390.04
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
Secured Loans
1,196.48
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
Unsecured Loans
569.75
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
Long Term Provisions
436.08
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
Current Liabilities
8,961.39
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
Trade Payables
2,958.16
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
Other Current Liabilities
2,274.32
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
Short Term Borrowings
3,015.56
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
Short Term Provisions
713.35
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
Total Liabilities
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
Net Block
9,719.35
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
Gross Block
20,183.69
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
Accumulated Depreciation
10,406.26
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
Non Current Assets
11,847.20
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
Capital Work in Progress
516.64
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
Non Current Investment
87.27
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
Long Term Loans & Adv.
307.83
320.65
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
Other Non Current Assets
1,216.11
47.82
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
Current Assets
16,798.58
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
Current Investments
1,059.11
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
Inventories
5,476.35
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
Sundry Debtors
5,497.10
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
Cash & Bank
3,142.33
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
Other Current Assets
1,623.69
1,428.05
1,519.98
497.54
1,300.77
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
Short Term Loans & Adv.
312.63
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
Net Current Assets
7,837.19
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
Total Assets
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
2,999.94
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
PBT
4,015.00
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
Adjustment
1,301.52
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
Changes in Working Capital
-1,410.54
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
Cash after chg. in Working capital
3,905.98
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-906.04
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,171.89
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
Net Fixed Assets
-900.14
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
Net Investments
-374.36
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
Others
-2,897.39
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
Cash from Financing Activity
1,731.88
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
Net Cash Inflow / Outflow
559.93
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
Opening Cash & Equivalents
983.76
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
Closing Cash & Equivalent
1,543.69
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
374.93
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
ROA
12.63%
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
ROE
21.13%
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
ROCE
21.97%
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
Fixed Asset Turnover
1.87
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
Receivable days
50.00
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
Inventory Days
51.19
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
Payable days
185.58
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
Cash Conversion Cycle
-84.38
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
Total Debt/Equity
0.30
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
Interest Cover
14.62
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Lupin launches Bosentan Tablets for Oral Suspension in United States
    20th Aug 2025, 11:00 AM

    NATCO holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

    Read More
  • Lupin partners with Sandoz Group AG
    12th Aug 2025, 14:40 PM

    The partnership is to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions

    Read More
  • Lupin launches Glucagon for Injection USP, 1mg/vial in United States
    11th Aug 2025, 11:50 AM

    Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of $122 million in the U.S.

    Read More
  • Lupin reports 52% rise in Q1 consolidated net profit
    6th Aug 2025, 12:16 PM

    The total consolidated income of the company increased by 11.98% at Rs 6347.38 crore for Q1FY26

    Read More
  • Lupin - Quarterly Results
    5th Aug 2025, 20:40 PM

    Read More
  • Lupin gets USFDA’s nod for Liraglutide and Glucagon Injectable Products
    24th Jul 2025, 14:30 PM

    Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

    Read More
  • USFDA concludes inspection at Lupin’s Pithampur Unit-2 manufacturing facility
    18th Jul 2025, 12:59 PM

    The inspection closed with the issuance of a Form-483 with four observations

    Read More
  • Lupin’s arm receives GMP certification from Therapeutic Goods Administration
    18th Jul 2025, 11:19 AM

    LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs

    Read More
  • USFDA concludes inspection at Lupin’s Pithampur unit 3 manufacturing facility
    18th Jul 2025, 10:22 AM

    The inspection closed with the issuance of a Form-483 with three observations

    Read More
  • Lupin launches Loteprednol Etabonate Ophthalmic Suspension in United States
    16th Jul 2025, 18:34 PM

    Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc

    Read More
  • Lupin signs license and supply agreement with Zentiva
    9th Jul 2025, 11:11 AM

    The agreement is for commercialization of the company’s biosimilar Certolizumab Pegol

    Read More
  • Lupin launches Ipratropium Bromide Nasal Solution in United States
    4th Jul 2025, 17:43 PM

    Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

    Read More
  • Lupin gets USFDA’s nod for Loteprednol Etabonate Ophthalmic Gel
    2nd Jul 2025, 09:07 AM

    Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity

    Read More
  • Lupin executes BTA for transfer of API R&D Division to Lupin Manufacturing Solutions
    1st Jul 2025, 11:53 AM

    In terms of the BTA, the said transaction has been completed and transfer of API R&D Division is effective from July 01, 2025

    Read More
  • Lupin executes BTA for transfer of OTC Business to LUPINLIFE Consumer Healthcare
    1st Jul 2025, 10:23 AM

    In terms of the BTA, the said transaction has been completed, and transfer of OTC Business is effective from July 01, 2025

    Read More
  • Lupin launches Prucalopride Tablets in United States
    26th Jun 2025, 16:30 PM

    Prucalopride Tablets, 1 mg, and 2 mg had estimated annual sales of $184 million in the U.S.

    Read More
  • Lupin gets USFDA’s nod for Prucalopride Tablets
    25th Jun 2025, 14:30 PM

    This product will be manufactured at Lupin’s Goa facility in India

    Read More
  • Lupin signs license and supply agreement with Sino Universal Pharmaceuticals
    16th Jun 2025, 11:10 AM

    This partnership will enable Lupin to expand its footprint in China

    Read More
  • Lupin gets USFDA’s approval for Oxcarbazepine ER tablets
    9th Jun 2025, 10:09 AM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin enters into license, supply agreement with SteinCares
    26th May 2025, 11:49 AM

    The companies have entered into agreement for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.